Welcome to our dedicated page for Sharps Technology SEC filings (Ticker: STSSW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sharps Technology Inc. filings document regulatory disclosures for a Nevada operating company with medical device sales and distribution activities and a Solana-focused digital asset treasury strategy. Current reports describe material agreements, at-the-market equity offering arrangements, executive officer appointments, indemnification agreements, committee changes, and capital-structure matters involving common stock and warrants.
Proxy statements disclose stockholder voting matters, including director elections, auditor ratification, equity incentive plan approvals, and authorization for warrant-related share issuances. The filing record also covers governance procedures, Nasdaq rule considerations, registration-statement use, and securities offering mechanics tied to the company’s common stock and warrant structure.
Altium Capital Management LLC, Altium Healthcare Long Short Onshore Fund LP and Altium Healthcare Long Short GP LLC jointly report beneficial ownership of 35,659 shares of Sharps Technology Inc. common stock issuable upon conversion of Series A warrants, representing 3.48% of the class based on 1,023,214 shares outstanding.
The filing notes the Series A warrants are subject to a 9.99% Warrant Blocker that prevents exercise to the extent it would raise ownership above that threshold. The cover-page figures include the full number of shares issuable on conversion and do not give effect to the Warrant Blocker, so the actual number of shares the reporting persons could beneficially own after giving effect to the blocker is less than the reported amount. Reported sole voting and dispositive power are 0, with 35,659 shared voting and dispositive power.
Sharps Technology, Inc. reported its first product revenue in the quarter of $222,722 and recorded a gross loss of $1,032,027 primarily driven by cost of goods and an inventory reserve. Total assets rose to $17,085,197 and cash increased to $8,322,192, reflecting net proceeds of approximately $18.2 million from a January 2025 equity offering and partial repayment of debt.
For the six months ended June 30, 2025 the company reported net income of $5,488,141, largely attributable to a noncash fair‑value gain on warrants of $11,087,700; warrant liabilities were $1,312,848 at period end. Management discloses substantial doubt about going concern and expects to seek additional financing. The filing also discloses legal claims including a lawsuit alleging up to $1.762 million and an arbitration claim of $500,000, plus equipment purchase commitments of approximately $4.7 million.